Literature DB >> 11016593

Immunopathologic weight loss in intracranial LCMV infection initiated by the anorexigenic effects of IL-1beta.

D Hildeman1, D Muller.   

Abstract

Lymphocytic choriomeningitis virus (LCMV) infection of beta2-microglobulin-deficient (beta2m-/-) mice results in a substantial loss of body weight that is not mediated by the virus itself, but rather by CD4+ T cells responding to the viral infection. In this study, we further characterized LCMV-induced weight loss in immunocompetent and beta32m-/- mice. We show that intracranial (i.c.), but not intraperitoneal (i.p.) LCMV infection elicited significant weight loss and that weight loss was preceded by anorexia. Also, uninfected mice fed an equivalent amount as eaten by infected mice had similar weight loss compared to their infected counterparts. Interestingly, both weight loss and anorexia were greater in female than male beta2m-/- mice. LCMV-infected female beta2m-/- mice also had significantly more interleukin (IL)-betag in their cerebrospinal fluid (CSF) than did male beta2m-/- mice. Finally, intracerebroventricular (i.c.v.) administration of anti-IL-1beta antibody, but not control immunoglobulin G (IgG), attenuated the initial weight loss and increased food intake. Taken together, these results suggest that the majority of weight loss after intracranial LCMV infection is the result of anorexia and IL-1beta mediates initial anorexic weight loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016593     DOI: 10.1089/08828240050144617

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  10 in total

1.  Androgens suppress antigen-specific T cell responses and IFN-γ production during intracranial LCMV infection.

Authors:  Adora A Lin; Sara E Wojciechowski; David A Hildeman
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

2.  Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production.

Authors:  Adora A Lin; Pulak K Tripathi; Allyson Sholl; Michael B Jordan; David A Hildeman
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

3.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 4.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells.

Authors:  R Ou; S Zhou; L Huang; D Moskophidis
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  Cell-mediated immunity to HIV in the female reproductive tract.

Authors:  Barbara L Shacklett
Journal:  J Reprod Immunol       Date:  2009-10-25       Impact factor: 4.054

7.  ICAM-5 modulates cytokine/chemokine production in the CNS during the course of herpes simplex virus type 1 infection.

Authors:  Margaret C L Tse; Crystal Lane; Kevin Mott; Nattawat Onlamoon; Hui-Mien Hsiao; Guey Chuen Perng
Journal:  J Neuroimmunol       Date:  2009-07-09       Impact factor: 3.478

Review 8.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

9.  Gene expression in primate liver during viral hemorrhagic fever.

Authors:  Mahmoud Djavani; Oswald R Crasta; Yan Zhang; Juan Carlos Zapata; Bruno Sobral; Melissa G Lechner; Joseph Bryant; Harry Davis; Maria S Salvato
Journal:  Virol J       Date:  2009-02-12       Impact factor: 4.099

Review 10.  The interplay of immunology and cachexia in infection and cancer.

Authors:  Hatoon Baazim; Laura Antonio-Herrera; Andreas Bergthaler
Journal:  Nat Rev Immunol       Date:  2021-10-04       Impact factor: 108.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.